TFEB Activators
The chemical class of T-TFEB activators encompasses a diverse array of compounds that intricately modulate the transcription factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy. These compounds, with their distinct mechanisms of action, collectively orchestrate a cellular symphony to promote TFEB activation and influence lysosomal homeostasis. Torin 1, a notable member of this chemical class, takes center stage as an mTOR inhibitor, indirectly unleashing TFEB by disrupting the mTORC1 complex. By relieving mTOR-mediated phosphorylation, Torin 1 allows TFEB to move to the nucleus, enhancing its transcriptional activity and promoting lysosomal biogenesis. The chemical composition of this class extends to PF-06409577, a dual PI3K/mTOR inhibitor, which influences TFEB activity by suppressing mTORC1 and mTORC2 activities. This compound conducts a harmonious modulation of the PI3K/mTOR pathway, guiding TFEB to the nucleus and enhancing its transcriptional prowess.
In the ensemble of T-TFEB activators, SB216763 takes on the role of a GSK-3 inhibitor, indirectly influencing TFEB by inhibiting GSK-3β. This inhibition harmonizes with the cellular orchestra, allowing TFEB to translocate to the nucleus and fine-tune its transcriptional performance. Verapamil, an L-type calcium channel blocker, brings a calcium-infused cadence to the T-TFEB activators. By modulating intracellular calcium levels, verapamil influences TFEB activity, orchestrating its nuclear translocation and enhancing lysosomal biogenesis. Rapamycin, a founding member of mTOR inhibitors, continues to resonate within this chemical class, directing the cellular symphony toward TFEB activation. By inhibiting the mTORC1 complex, rapamycin paves the way for TFEB to play its transcriptional melody in the nucleus, regulating lysosomal biogenesis and autophagy. Ronidazole, an antiprotozoal agent, introduces a rhythmic modulation by influencing autophagy-related pathways. By promoting autophagic flux, ronidazole guides TFEB nuclear translocation, contributing to its transcriptional performance.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin 1, an mTOR inhibitor, indirectly activates TFEB by inhibiting the mTORC1 complex. By relieving mTOR-mediated phosphorylation, Torin 1 promotes TFEB translocation to the nucleus, enhancing its transcriptional activity. This compound represents a key regulator of TFEB activity through the mTOR signaling pathway, offering a mechanistic approach to modulate TFEB-dependent lysosomal biogenesis and autophagy. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR, an AMPK activator, indirectly activates TFEB by promoting AMPK-mediated phosphorylation. Through AMPK activation, AICAR triggers TFEB nuclear translocation, enhancing its transcriptional activity. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil, an L-type calcium channel blocker, indirectly activates TFEB by modulating intracellular calcium levels. By influencing calcium-dependent signaling pathways, verapamil promotes TFEB nuclear translocation and enhances its transcriptional activity. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-Deoxyglucose, a glycolytic inhibitor, indirectly activates TFEB by modulating cellular energy metabolism. By inhibiting glycolysis, 2-deoxyglucose activates AMPK, promoting TFEB phosphorylation and nuclear translocation. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $38.00 $79.00 $188.00 $520.00 $1248.00 $5930.00 | 8 | |
Niclosamide, an anthelmintic drug, indirectly activates TFEB by inhibiting the mTORC1 complex. By suppressing mTOR activity, niclosamide promotes TFEB nuclear translocation and enhances its transcriptional activity. | ||||||
Ronidazole | 7681-76-7 | sc-212789 | 1 g | $333.00 | ||
Ronidazole, an antiprotozoal agent, indirectly activates TFEB by modulating autophagy-related pathways. By promoting autophagic flux, ronidazole facilitates TFEB nuclear translocation and enhances its transcriptional activity. | ||||||
MRT 68921 | 1190379-70-4 | sc-507429 | 10 mg | $276.00 | ||
MRT68921, an ULK1 inhibitor, indirectly activates TFEB by modulating autophagy-related signaling. By inhibiting ULK1 activity, MRT68921 promotes TFEB nuclear translocation and enhances its transcriptional activity. | ||||||
Dorsomorphin dihydrochloride | 1219168-18-9 | sc-361173 sc-361173A | 10 mg 50 mg | $186.00 $751.00 | 28 | |
Dorsomorphin, an AMPK inhibitor, indirectly activates TFEB by modulating cellular energy sensing pathways. By inhibiting AMPK, dorsomorphin triggers TFEB dephosphorylation and nuclear translocation. | ||||||
SQ 22536 | 17318-31-9 | sc-201572 sc-201572A | 5 mg 25 mg | $95.00 $363.00 | 13 | |
SQ22536, an adenylyl cyclase inhibitor, indirectly activates TFEB by modulating cAMP signaling. By suppressing cAMP production, SQ22536 promotes TFEB nuclear translocation and enhances its transcriptional activity. | ||||||